NanoTx Therapeutics

NanoTx Therapeutics was a clinical-stage biotechnology company focused on developing targeted therapies for central nervous system (CNS) malignancies, with a primary emphasis on glioblastoma. The company's lead asset, NTX-101, was a highly brain-penetrant, small molecule inhibitor of the Epidermal Growth Factor Receptor (EGFR), designed to overcome the blood-brain barrier. Founded as a spin-off from the University of California, Los Angeles (UCLA), NanoTx leveraged proprietary research into oncogenic signaling to address unmet needs in neuro-oncology. In July 2020, the company's assets were acquired by Plus Therapeutics to bolster their pipeline of CNS-focused treatments. The acquisition included all intellectual property and clinical data related to the NTX-101 program.